Before describing the findings, an important caveat deserves emphasis, and the researchers themselves make it explicitly. The study does not mean that having a stroke causes brain cancer. The causes of most gliomas remain unknown, and population-level observations that link a prior history of brain injury to later brain tumors do not prove that one causes the other. Correlation in epidemiological data can arise from many confounding factors, and a statistical association alone cannot reveal the underlying biology. What the team set out to ask instead was a more precise and experimentally tractable question: whether a prior history of stroke can change the brain environment in ways that promote the progression of glioma cells already present. Using multiple experimental models, including models incorporating glioma cells derived from patients, the researchers consistently found that stroke accelerated glioma growth and increased the spread of tumor cells into the areas of the brain affected by the stroke. The distinction between causing a tumor and fueling one that already exists is central to interpreting the work.

The motivation for the study grew out of a gap in the scientific literature. Previous population studies had reported an association between brain injury, including stroke, and brain tumors, but scientists did not understand the biological mechanisms that might connect the two. Without a mechanism, such associations remain difficult to interpret and impossible to act upon therapeutically. The new research, for which Ye and Hyun Kyoung Lee of Baylor College of Medicine and Texas Children’s Hospital conceived the project and designed the experiments, with Christine Madamba of Baylor and the Duncan Neurological Research Institute serving as co-first author alongside Ye, was designed to close that gap by moving from correlation to causation in controlled laboratory systems. Most of the experimental work was conducted while Ye was a postdoctoral associate at Baylor, before she established her own laboratory at Virginia Tech.

To understand what was driving the accelerated tumor progression, the researchers looked beyond the cancer cells themselves and examined their neighbors. A tumor is never an isolated mass of malignant cells; it is embedded in a complex community of non-cancerous cells collectively known as the tumor microenvironment. In the brain, this community includes immune cells that patrol for damage and infection, as well as star-shaped glial cells called astrocytes, which perform some of the most essential housekeeping functions in the central nervous system. Astrocytes help maintain the normal chemical and structural milieu of the brain, regulate blood flow, support synapses, and respond vigorously to injury. After a stroke, the researchers found significant changes in this microenvironment, including alterations in both the immune cells and the astrocytes surrounding the tumor. The injury response, in other words, had reshaped the cellular neighborhood in which glioma cells live.

One of the most striking discoveries involved calcium signaling, a fundamental mechanism by which astrocytes communicate with one another and regulate their internal functions. Astrocytes normally display rhythmic waves of calcium activity, and these signals are critical for coordinating their responses to changes in the brain. The researchers identified a distinct population of tumor-associated astrocytes that emerged after stroke and showed substantially reduced calcium activity compared with their normal counterparts. In effect, the stroke had produced a specialized subpopulation of astrocytes whose communication behavior had been dampened, and these cells were found in association with the tumor. The question then became whether this altered signaling was merely a byproduct of the injury or an active contributor to tumor progression.

The team answered that question through a direct experimental test. When the researchers experimentally restored calcium signaling in the astrocytes, they reduced the stroke-associated increase in tumor growth and cancer cell proliferation. This result demonstrated that the dampened calcium activity was not incidental; it was functionally linked to the accelerated progression of the cancer. By restoring a normal property of the astrocytes, the pathological advantage conferred by the stroke environment could be partially reversed. The finding is technically significant because it establishes a causal chain running from stroke-induced changes in glial cell behavior to measurable changes in tumor biology, rather than merely documenting that both occur at the same time.

The researchers went a step further and identified a specific molecular regulator of the process: a protein called SLC4A4. When the team increased the amount of this protein in astrocytes, calcium activity was restored, tumor growth was reduced, and survival was prolonged in experimental models. Removing the protein produced the opposite effects, worsening the outcome. SLC4A4, which functions as a solute carrier involved in transporting bicarbonate across cell membranes and thereby influences cellular pH regulation, thus emerged as a key node connecting astrocyte physiology to tumor behavior. The dose-dependent relationship, in which more of the protein produced better outcomes and less produced worse ones, strengthens the case that this molecule is genuinely part of the mechanism rather than a passive marker of disease state.

For Ye, the findings illustrate a sobering principle about how glioma cells operate within the brain. “What we found is that glioma cells can take advantage of the same processes the brain uses to repair itself after an injury to help the tumor progress,” she said. “They integrate into the brain and use every chance to progress. We need to understand how they do that and then find ways to stop it.” She reiterated the point in a broader framing: “Glioma cells can use the brain’s intrinsic repair system to progress. They integrate into the brain and take advantage of those changes.” The idea that a tumor can co-opt endogenous healing mechanisms is not unique to glioma research, but demonstrating it concretely in the context of stroke injury, with a defined cell type and a defined molecular regulator, gives the concept unusual experimental clarity.

The therapeutic implications are already shaping the next phase of the research. The team is now investigating whether the mechanisms identified in the study could provide targets for future treatments. “This study opens many exciting new questions,” Ye said. “We identified genes and biological pathways that may help explain how an injured brain environment influences glioma progression. Now we want to understand whether some of them could become therapeutic targets for a disease that remains largely incurable. I’m excited to bring some of these unanswered questions to my new lab at Virginia Tech’s Fralin Biomedical Research Institute and continue pursuing them there.” Glioblastoma and related gliomas carry some of the poorest prognoses in oncology, and standard treatments of surgery, radiation, and chemotherapy have produced only incremental gains, which is why strategies aimed at the tumor microenvironment rather than the cancer cells alone have attracted growing interest.

The study also carries a broader message about the brain as a dynamic environment rather than a passive backdrop for disease. Injury, aging, inflammation, and other systemic changes can remodel the cellular and molecular landscape of the central nervous system, and cells that dwell within that landscape, whether healthy or malignant, respond to the remodel. By showing that a stroke-induced shift in astrocyte calcium signaling, governed in part by SLC4A4, can tip the balance toward faster tumor growth and wider spread, the researchers have provided a concrete example of environment-driven cancer progression in the brain. The work, published in Nature Cancer on 25 September 2026 under the title describing stroke-driven glioma progression through the emergence of tumor-associated astrocytes with reduced calcium activity, was an experimental study conducted at the cellular level. It does not change clinical guidance for stroke survivors, who should not interpret the findings as a warning about cancer risk, but it does give researchers a new set of genes, pathways, and cell states to interrogate as they search for leverage against one of medicine’s most stubborn cancers.

Subject of Research: How stroke-induced changes in astrocyte calcium signaling and the tumor microenvironment accelerate glioma progression

Article Title: Brain’s response to stroke injury may advance tumor’s progression

Article References: Brain’s response to stroke injury may advance tumor’s progression. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, stroke, astrocytes, calcium signaling, SLC4A4, tumor microenvironment, Nature Cancer, brain injury, tumor progression, Virginia Tech, Baylor College of Medicine, cancer research

The team set out to test whether the connection between brain injury and glioma was more than coincidence. Drawing on population-based studies that had linked stroke, traumatic brain injury, and other neurological insults to increased brain cancer incidence, the researchers engineered a series of preclinical models in which mice experienced an induced ischemic stroke before or after glioma cells were introduced into the brain. The results were striking. In both patient-derived xenograft models and genetically engineered high-grade glioma models, tumors implanted into brains that had experienced a stroke grew larger, invaded more aggressively into surrounding cortical tissue, and in one model spread significantly further into the injured cortex compared with tumors in sham-operated controls. Mice with stroke-primed gliomas also showed reduced overall survival, and even a slower-growing low-grade glioma model showed increased tumor cellularity after stroke exposure.

Crucially, the phenomenon was not limited to mice. When the researchers compared transcriptional profiles from human high-grade glioma samples in The Cancer Genome Atlas with gene expression data from patients who had suffered stroke, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and schizophrenia, they found that stroke showed the strongest molecular overlap with glioma. Genes that were coordinately upregulated or downregulated in both conditions pointed to a shared injury-response program, suggesting that the biology the team uncovered in mice has echoes in human disease. Single-cell RNA sequencing and spatial transcriptomics of tumor-bearing brains then revealed what that program actually involved: a wholesale remodeling of the tumor microenvironment at the invasive edge of the tumor.

At the heart of the discovery is a specialized astrocyte population the authors call tumor-associated astrocytes, or TAAs. Astrocytes are star-shaped glial cells that normally support neurons, regulate neurotransmitters, and maintain the blood-brain barrier. In healthy tissue, they communicate through rhythmic surges of intracellular calcium ions, or Ca2+ activity, which coordinate their metabolic and signaling functions. The team found that in the stroke-primed tumors, a distinct subset of these astrocytes emerged at the tumor’s invasive front with a remarkable property: their spontaneous calcium signaling was markedly dampened. The researchers dubbed this population stroke-induced tumor-associated astrocytes, and their reduced calcium oscillations appeared to be a functional change, not merely a byproduct of injury, because astrocytes located far from the stroke lesion retained normal activity.

Why would quieter astrocytes help a tumor? The answer, the study shows, lies in the immune landscape of the glioma. Using computational tools that map ligand-receptor communication between cell types, the researchers found that the calcium-suppressed astrocytes expressed elevated levels of CCL2, a chemokine well known for attracting immune cells bearing the CCR2 receptor. This signal acted as a beacon for tumor-associated microglia and macrophages, collectively called TAMs, which accumulated in the invasive margin of stroke-primed tumors. TAMs are a double-edged sword in brain cancer: while they can theoretically attack tumor cells, they more often nurture them, secreting growth factors, suppressing anti-tumor immunity, and paving the way for invasion. The density of these myeloid cells in the stroke-remodeled environment gave the tumor exactly the kind of accomplice it needed to expand into injured tissue.

The causal chain was confirmed through a series of elegant perturbation experiments. When the researchers pharmacologically depleted TAMs in stroke-primed mice using a CSF1R inhibitor, the stroke-driven acceleration of tumor growth was largely abolished. Similarly, when they used engineered receptor tools to artificially restore calcium activity in the tumor-associated astrocytes, either by activating Gq-coupled designer receptors or by other calcium-restoring manipulations, the astrocytes resumed a more normal signaling profile, CCL2 expression fell, macrophage recruitment declined, and tumor progression slowed. These reciprocal experiments demonstrate that neither the astrocyte change nor the macrophage influx alone is sufficient; it is the astrocyte-to-macrophage signaling axis that transmits the stroke injury into tumor-promoting action.

The team then traced the molecular switch that silences astrocyte calcium signaling after stroke. Their search converged on SLC4A4, a gene encoding the electrogenic sodium-bicarbonate cotransporter NBCe1, a protein that regulates intracellular pH by moving bicarbonate across the cell membrane. The group had previously shown that astrocytic SLC4A4 helps maintain blood-brain barrier integrity through a CCL2-CCR2 pathway, making it a plausible candidate in the current context. In the new study, single-cell analysis revealed that SLC4A4 was enriched in tumor-associated astrocytes, and that its expression correlated with robust calcium activity. When the researchers genetically deleted Slc4a4 specifically from astrocytes in mice, the astrocytes’ calcium signaling collapsed, CCL2 expression rose, TAMs flooded into the tumor, and gliomas grew faster and larger across two independent models. Conversely, overexpressing SLC4A4 in astrocytes boosted their calcium activity and suppressed tumor growth, even blunting the stroke-induced acceleration of cortical invasion.

The genetic logic of the pathway was sealed with combination experiments. When the researchers deleted Slc4a4 together with Ccl2 from astrocytes, or deleted Slc4a4 while simultaneously depleting TAMs pharmacologically, the aggressive tumor phenotype caused by Slc4a4 loss was reversed. In other words, the entire tumor-promoting effect of a calcium-silenced astrocyte depends on its ability to recruit myeloid cells through CCL2. Interrupt that recruitment, and the tumor loses its stroke-widened path of invasion. Computational modeling of cell-cell communication reinforced this conclusion, showing that SLC4A4-low astrocytes behave as dominant signaling senders toward tumor cells, with a dense web of ligand-receptor interactions that disappears when the pathway is genetically or pharmacologically interrupted.

Beyond its immediate findings, the study carries broader implications for how scientists think about the relationship between brain injury and cancer. Recent work from other groups has shown that gliomagenesis can mimic an injury-response program and that injury can prime mutation-bearing glial cells for malignant dedifferentiation, while neuronal activity itself has been shown to drive glioma progression through secreted factors. The new results add a precise mechanistic layer to this emerging picture: the brain’s own first responders to injury, the astrocytes, can be reprogrammed into a state that is permissive, even hospitable, to malignant growth. Calcium signaling, long studied in the context of synaptic support and gliotransmission, now appears to function as a tumor-suppressive gatekeeper in the glioma microenvironment.

Therapeutically, the work suggests several points of intervention. If clinical studies confirm that stroke history reshapes the microenvironment of human gliomas, then patients with prior strokes might benefit from intensified surveillance, and treatments aimed at restoring astrocyte calcium homeostasis, blocking CCL2-mediated myeloid recruitment, or depleting tumor-promoting macrophages could complement existing surgical, radiation, and immunotherapeutic approaches. Compounds that modulate bicarbonate transport or pH regulation in astrocytes, or chemokine-blocking agents already in development for other diseases, could find new applications in neuro-oncology. For now, the study stands as a vivid demonstration that the boundary between neurological disease and cancer is thinner than once believed, and that the injured brain can become an unwitting accomplice to the tumors that grow within it.

Subject of Research: How stroke-induced changes in astrocyte calcium signaling and macrophage recruitment promote glioma progression

Article Title: Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca2+ activity

Article References: Ye, Q., Madamba, C., Woo, J., Choy, T. J., Wheeler, K. F., Zhan, J., Cristobal, C. D., Spjut, C., Shin, D., Jo, J., Ailani, R. R., Smith, J., Latha, K., Harmanci, A. S., Yalamanchili, H. K., Gallo, M., Yun, K., Reshetnyak, Y. K., Kim, E., … Lee, H. K. (2026). Stroke drives glioma progression through the emergence of tumor-associated astrocytes with reduced Ca2+ activity. Nature Cancer. https://doi.org/10.1038/s43018-026-01238-8

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01238-8

Keywords: glioma, stroke, astrocytes, calcium signaling, tumor-associated macrophages, CCL2, SLC4A4, tumor microenvironment, brain injury, Nature Cancer, neuro-oncology, invasion

The study began with three unrelated children who shared an unusual constellation of symptoms: abnormally large heads beginning in infancy, recurrent episodes of elevated pressure inside the skull, difficulties with movement and coordination, autistic features, and seizures. Magnetic resonance imaging revealed a distinctive pattern of edema, with swelling initially confined to the outermost layers of cerebral cortex before spreading into the underlying white matter. Unusual signal changes in the medulla, the lower portion of the brainstem, further distinguished these cases from better-known causes of genetic brain edema.

Genetic sequencing uncovered the culprit: a heterozygous missense variant in SLC4A4, the gene encoding the electrogenic sodium bicarbonate cotransporter NBCe1. This variant, absent from population databases, substitutes a threonine for a highly conserved isoleucine residue in the eighth transmembrane domain of the protein. The residue sits immediately below the ion coordination site, a position critical for the transporter’s ability to shuttle bicarbonate across cell membranes while maintaining proper electrochemical gradients.

Importantly, the clinical picture differed dramatically from proximal renal tubular acidosis, the condition classically associated with biallelic loss-of-function mutations in SLC4A4. Children with that disorder suffer from systemic acidosis, short stature, and eye and tooth abnormalities, but they do not develop chronic brain edema. The patients in this study showed only mild laboratory evidence of acidosis and no overt renal symptoms, indicating that the new variant causes disease through a mechanism distinct from simple protein inactivation.

To understand how the mutation wreaks havoc at the molecular level, researchers used confocal imaging, patch-clamp electrophysiology, and voltage-clamp studies in frog oocytes. They found that the mutant protein reaches the cell membrane far less efficiently than its normal counterpart. More strikingly, even the fraction that does reach the surface behaves aberrantly: instead of cleanly transporting sodium and bicarbonate together, the mutant transporter admits a continuous, weakly selective depolarizing current that leaks positive ions into cells, disrupting membrane potential.

This depolarizing leak proved consequential for astrocytes, the star-shaped glial cells that express NBCe1 more abundantly than any other brain cell type. Immunohistochemistry on human brain tissue confirmed dense NBCe1 staining in astrocytic processes throughout gray and white matter, particularly at blood-brain interfaces. Astrocytes normally rely on NBCe1 to buffer extracellular acidity generated by neuronal firing, and the transporter can move bicarbonate in either direction depending on the cell’s membrane voltage. The leak shifts astrocytes toward inward bicarbonate transport even at rest, promoting cellular swelling and, ultimately, tissue-wide edema.

Structural modeling using AlphaFold 3 did not reveal an obvious pore or channel forming in the mutant protein, suggesting instead that the leak arises from a subtle destabilization of the conformational switching mechanism that transporters use to ferry substrates across membranes. Similar mutations in related SLC4 family members, such as the red cell anion exchanger AE1, have been shown to convert disciplined transporters into indiscriminate cation leaks, hinting at a broader principle of transporter dysfunction that this study now extends to the brain.

The translational payoff emerged when researchers tested oral bicarbonate supplementation in two of the affected children. Over nearly two years of treatment, both showed marked clinical improvement, including better motor control, enhanced social engagement, and normalization of head growth rate. Sequential brain MRIs demonstrated reduced white matter edema, resolution of brainstem abnormalities, and improved quantitative diffusion measures, confirming that restoring extracellular bicarbonate can dampen the pathological leak and relieve astrocyte swelling.

The work establishes SLC4A4-related encephalopathy as a new member of a small family of astrocyte-driven brain edema disorders, alongside megalencephalic leukoencephalopathy with subcortical cysts. By connecting acid-base regulation directly to brain volume control, the findings underscore that pH homeostasis is not merely a supporting player in brain physiology but a central determinant of tissue integrity. They also raise the prospect that other unexplained cases of childhood macrocephaly and edema may respond to the same simple metabolic intervention.

The connection between pH regulation and intracranial pressure has long been appreciated in clinical practice, most visibly in the use of controlled hyperventilation to lower arterial carbon dioxide. When CO2 falls, extracellular fluid becomes alkaline, cerebral vessels constrict, and pressure within the skull drops. What the new study adds to this familiar picture is a genetic demonstration that the converse relationship also holds: when bicarbonate handling at the single-cell level is disrupted, brain tissue volume can spiral upward chronically rather than fluctuating with ventilation. In this sense, the SLC4A4 variant provides a natural experiment that isolates acid-base transport as a direct determinant of brain water distribution, something that pharmacological manipulation alone could never cleanly establish.

The quantitative imaging methods used to track the patients deserve particular attention. Beyond conventional T2 and FLAIR sequences, the investigators extracted diffusion-weighted metrics from defined regions of interest, including mean diffusivity, fractional anisotropy, and radial diffusivity. These measures probe the microscopic architecture of white matter: mean diffusivity rises when extracellular water accumulates and tissue microstructure breaks down, while radial diffusivity is sensitive to the integrity of the myelin sheaths surrounding axons. Serial measurements of this kind allowed the team to document not just visible swelling but subtle changes in tissue microstructure over years, and then to watch those same metrics improve during bicarbonate therapy. Such longitudinal quantitative imaging is still uncommon in rare-disease research and offers an objective endpoint for future trials.

The inheritance patterns observed across the four affected individuals carry practical implications for genetic counseling. In two of the children, the variant was absent from both parents, consistent with a de novo event, meaning that recurrence risk for subsequent siblings is low though not zero due to the possibility of germline mosaicism. The third child, however, inherited the variant from his mother, who herself only became symptomatic in mid-adulthood after minor head trauma. This markedly later and milder presentation in the transmitting parent illustrates how the same molecular defect can produce dramatically different clinical trajectories, likely reflecting a combination of modifier genes, environmental insults, and the cumulative burden of edema episodes over decades. It also serves as a caution that heterozygous SLC4A4 carriers should not be assumed to be unaffected simply because they lack the severe infantile phenotype.

The episodic nature of the patients’ deterioration is itself informative. Recurrent crises of raised intracranial pressure were repeatedly triggered by minor head trauma or intercurrent infections, and responded to corticosteroids and, in one child, to acetazolamide, a carbonic anhydrase inhibitor that reduces cerebrospinal fluid production and shifts acid-base balance. These triggers plausibly act by imposing additional osmotic or inflammatory stress on astrocytes whose buffering capacity is already compromised by the leaky transporter. The observation that systemic infections can precipitate neurological decompensation echoes patterns seen in other channelopathies and suggests that fever, altered ventilation, and metabolic acidosis during illness may transiently worsen the already deranged bicarbonate equilibrium in these patients’ brains.

The radiating pattern of enlarged perivascular spaces visible on the patients’ scans offers a further clue to the underlying pathology. Perivascular spaces are fluid-filled compartments that follow vessels deep into the brain parenchyma, and their enlargement is typically interpreted as impaired clearance of interstitial fluid. In this disorder, their prominence in the swollen white matter suggests that the edema fluid is not uniformly distributed but accumulates along perivascular drainage routes, consistent with astrocytic endfeet at the blood-brain interface being a primary site of pathological swelling. The dense NBCe1 staining observed at these same interfaces in human control tissue strengthens the argument that the blood-brain boundary is where the mutant transporter exerts its greatest damage.

Comparison with megalencephalic leukoencephalopathy with subcortical cysts, the prototypical monogenic brain edema disorder, highlights both similarities and differences. MLC arises from defects in MLC1, GlialCAM, GPRC5B, or aquaporin-4, proteins that govern astrocyte volume regulation and cell-cell adhesion, yet none of these directly implicate acid-base transport. The shared imaging signature, subcortical white matter swelling with cyst formation and temporal lobe involvement, suggests convergent downstream pathways, but the response to bicarbonate in the SLC4A4 patients raises the question of whether subtle pH disturbances might also contribute to edema in MLC, or whether bicarbonate therapy might have adjunctive value there. Testing such hypotheses will require careful metabolic monitoring, since the patients here showed only mild serum bicarbonate reduction despite dramatic neurological benefit from supplementation.

The mechanistic finding that a transporter can become a cation leak without forming an obvious pore has implications well beyond this one gene. SLC4 family members and related transporter superfamilies are increasingly recognized as capable of adopting leak modes when their conformational gating is destabilized, and the parallel with the anion exchanger AE1 in red blood cells suggests a shared biophysical principle. For clinicians, the message is that missense variants in transporter genes cannot be assumed to be simple loss-of-function; electrophysiological characterization may reveal gain-of-toxic-function behavior with entirely distinct tissue consequences and, as demonstrated here, distinct treatment opportunities. Screening unexplained childhood macrocephaly cases for SLC4A4 variants, and considering early bicarbonate supplementation when such variants are found, now stands as a concrete clinical action supported by this work.

Subject of Research: NBCe1 sodium bicarbonate cotransporter dysfunction causing genetic brain edema in children

Article Title: A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema

Article References: Bisseling, Q., Parker, M. D., Kerst, S., Pasternack, R. A., Tondreau, J., Breur, M., van Rooijen‐van Leeuwen, G. M., Tonduti, D., Salsano, E., Darling, A., van Wijk, J. A. E., Törnroth‐Horsefield, S., Bugiani, M., Pouwels, P. J. W., Waisfisz, Q., van der Knaap, M. S., & Min, R. (2026). A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema. Annals of Clinical and Translational Neurology, 13(9), 1817-1830. https://doi.org/10.1002/acn3.70363

Image Credits: AI Generated

DOI: 10.1002/acn3.70363

Keywords: NBCe1, SLC4A4, brain edema, astrocytes, bicarbonate transporter, macrocphaly, intracranial pressure, acid-base homeostasis, ion leak, genetic encephalopathy, bicarbonate treatment, MRI